Groupe Francophone Des Myelodysplasies
Clinical trials sponsored by Groupe Francophone Des Myelodysplasies, explained in plain language.
-
New drug trial targets rare and devastating VEXAS syndrome
Disease control Recruiting nowThis study is testing whether the drug momelotinib can help control symptoms in adults with VEXAS syndrome, a rare and serious inflammatory condition. Participants will take the drug daily along with their current steroid medication to see if it reduces disease symptoms and allow…
Phase: PHASE2 • Sponsor: Groupe Francophone des Myelodysplasies • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New drug combo tested for blood disorder after standard treatment fails
Disease control Recruiting nowThis study is testing whether combining two drugs, luspatercept and ESA, works better than luspatercept alone for patients with a lower-risk type of bone marrow disorder called MDS. It is for adults whose disease has not improved or has returned after a common first treatment. Th…
Phase: PHASE1, PHASE2 • Sponsor: Groupe Francophone des Myelodysplasies • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC